Neurocrine Biosciences Inc
NASDAQ:NBIX

Watchlist Manager
Neurocrine Biosciences Inc Logo
Neurocrine Biosciences Inc
NASDAQ:NBIX
Watchlist
Price: 142.165 USD -1%
Market Cap: 14.1B USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

NBIX Price Targets Summary
Neurocrine Biosciences Inc

Wall Street analysts forecast NBIX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NBIX is 168.678 USD with a low forecast of 125.24 USD and a high forecast of 210 USD.

NBIX Lowest Forecast
Wall Street Target
125.24 USD
12% Downside
NBIX Average Forecast
Wall Street Target
168.678 USD
19% Upside
NBIX Highest Forecast
Wall Street Target
210 USD
48% Upside
Lowest
Price Target
125.24 USD
12% Downside
Average
Price Target
168.678 USD
19% Upside
Highest
Price Target
210 USD
48% Upside
Neurocrine Biosciences Inc Competitors:
Price Targets
URGN
Urogen Pharma Ltd
72% Upside
MCRB
Seres Therapeutics Inc
183% Upside
300601
Shenzhen Kangtai Biological Products Co Ltd
3% Upside
D
CRVO
Diffusion Pharmaceuticals Inc
127% Upside
URGN
Urogen Pharma Ltd
72% Upside
MCRB
Seres Therapeutics Inc
183% Upside
300601
Shenzhen Kangtai Biological Products Co Ltd
3% Upside
D
CRVO
Diffusion Pharmaceuticals Inc
127% Upside
N
4893
Noile-Immune Biotech Inc
133% Upside
GRAL
Grail Inc
7% Upside
LTRN
Lantern Pharma Inc.
428% Upside
REGN
Regeneron Pharmaceuticals Inc
33% Upside

Revenue
Forecast

Revenue Estimate
Neurocrine Biosciences Inc

For the last 13 years the compound annual growth rate for Neurocrine Biosciences Inc's revenue is 30%. The projected CAGR for the next 3 years is 16%.

30%
Past Growth
16%
Estimated Growth
Estimates Accuracy
-2%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Neurocrine Biosciences Inc

For the last 13 years the compound annual growth rate for Neurocrine Biosciences Inc's operating income is 24%. The projected CAGR for the next 3 years is 25%.

24%
Past Growth
25%
Estimated Growth
Estimates Accuracy
0%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Neurocrine Biosciences Inc

For the last 13 years the compound annual growth rate for Neurocrine Biosciences Inc's net income is 18%. The projected CAGR for the next 3 years is 35%.

18%
Past Growth
35%
Estimated Growth
Estimates Accuracy
-17%
Average Miss
What are analyst estimates?

See Also

Summary
NBIX intrinsic value, competitors valuation, and company profile.
DCF Valuation
NBIX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
NBIX stock valuation using valuation multiples.
Wall Street Estimates
NBIX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
NBIX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is NBIX's stock price target?
Price Target
168.678 USD

According to Wall Street analysts, the average 1-year price target for NBIX is 168.678 USD with a low forecast of 125.24 USD and a high forecast of 210 USD.

What is Neurocrine Biosciences Inc's Revenue forecast?
Projected CAGR
16%

For the last 13 years the compound annual growth rate for Neurocrine Biosciences Inc's revenue is 30%. The projected CAGR for the next 3 years is 16%.

What is Neurocrine Biosciences Inc's Operating Income forecast?
Projected CAGR
25%

For the last 13 years the compound annual growth rate for Neurocrine Biosciences Inc's operating income is 24%. The projected CAGR for the next 3 years is 25%.

What is Neurocrine Biosciences Inc's Net Income forecast?
Projected CAGR
35%

For the last 13 years the compound annual growth rate for Neurocrine Biosciences Inc's net income is 18%. The projected CAGR for the next 3 years is 35%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 281,700+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.